Clinical studies of ImaRx’s lead product candidate, SonoLysis, have demonstrated the power of nanobubbles in conjunction with ultrasound to break up blood clots. Under the NHLBI grant award, the company will develop new, highly selective nanobubbles for targeted blood clot treatment in patients suffering from heart attack.
“Selectivity through targeted delivery is the key to the development of more effective and safer alternatives to current treatment paradigms,” said Dr Terry Matsunaga, vice president research, ImaRx.
“Because they are designed to find areas of thrombosis, where they are activated by ultrasound waves to mechanically break apart clots, our targeted nanobubbles in conjunction with ultrasound are a potentially safer option for MI (myocardial infarction) treatment than standard of care treatments such as lytic drugs and emergency thrombectomies,” added Dr Matsunaga.